Pharmacological treatment of diabetic retinopathy;Medikamentöse therapie der diabetischen retinopathie

Ophthalmologe

Volumn 101, Issue 12, 2004, Pages 1165-1170

  Lang, G E ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Diabetic retinopathy; Octreotide; Protein kinase C inhibitor; Somatostatin analogue; Triamcinolone acetonide

Indexed keywords

CALDESMON; DIACYLGLYCEROL; GLUCOSE; GROWTH HORMONE; OCTREOTIDE; PHORBOL ESTER; PROTEIN KINASE C; PROTEIN KINASE C BETA INHIBITOR; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TALIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; VIMENTIN;

ARTICLE; CATARACT; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; ENZYME BLOOD LEVEL; HORMONE SYNTHESIS; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; RETINA MACULA EDEMA;

ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS; CLINICAL TRIALS, PHASE III; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; HUMANS; INJECTIONS; MACULAR EDEMA, CYSTOID; MULTICENTER STUDIES; OCTREOTIDE; PROSPECTIVE STUDIES; PROTEIN KINASE C; SOMATOSTATIN; TRIAMCINOLONE ACETONIDE; VITREOUS BODY;

EID: 12144270463     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-004-1141-y     Document Type: Article

References (30)

1. Aiello LP, Bursell SE, Clermont A et al. (1997) Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 46:1473-1480
2. Baldysiak-Figiel A, Lang GK, Kampmeier J, Lang GE (2004) Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia. J Endocrinol 180:417-424
3. Böhm BO, Lang GK, Jehle PM, Feldmann B, Lang GE (2001) Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-rsk proliferative diabetic retinopathy. Horm Metab Res 33:300-306
4. Böhm BO, Lang GE, Volpert O et al. (2003) Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy. Diabetologica 46:394-400
5. Chakravarthy U, Hayes R, Stitt A et al. (1998) Constitutive nitric oxide synthase expression in retinal vascular endothelial cells is suppressed by high glucose and advanced glycation end-products. Diabetes 47:945-952
6. Craven PA, Davidson CM, DeRubertis FR (1990) Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes 39:667-674
7. Fauser S, Krohne T, Kirchhof B, Joussen AM (2003) Die diabetische Makulopathie - Klinik und Therapie. Klin Monatsbl Augenheilkd 220:526-531
8. 1-transcriptional activity in a reporter mesangial cell line. Am J Physiol 267:632-638
9. Grant MB, Mames RN, Fitzgerald C, Hahariwala KM, Cooper-DeHoff R, Caballero S, Estes KS (2000) The efficacy of octreotide in the therapy of severe non-proliferative and early proliferative diabetic retinopathy. Diabetes Care 23:504-509
10. Grant MB, Caballero S, Smith LEH (2002) Somatostatin in diabetic eye diseases. In: Lamberts SWJ, Ghigo E (eds) The expanding role of Octreotide. II: Advances in endocrinology and eye diseases. DioScientifica, Bristol, S 165-184
11. Hayashi A, Seki N, Hattori A et al. (1999) PKCnu, a new member of the protein kinase C family, composes a fourth subfamily with PKCmu. Biochem Biophys Acta 1450:99-106
12. Idris I, Gray S, Donnelly R (2001) Protein kinase C activation: isoenzyme-specific effects on metabolism and cardiovascular complications in diabetes. Diabetologica 44:659-673
13. Inoue M, Kishimoto A, Takai Y, Nishizuka Y (1977) Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. II. Proenzyme and its activation by calcium-dependent protease from rat brain. J Biol Chem 252:7610-7616
14. Ishii H, Jirousek MR, Koya D et al. (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKC-β inhibitor. Science 272:728-731
15. Jonas JB, Degenring R (2002) Intravitreale Injektion von kristallinem Triamcinolon Acetonid als Therapie des diffusen diabetischen Makulaödems. Klin Monatsbl Augenheilkd 219:429-432
16. Jonas JB, Kreissig I, Degenring RF (2003) Therapie intraokulärer ödematöser, proliferativer und neovaskulärer Erkrankungen durch intravitreales Triamcinolon Acetonid. Klin Monatsbl Augenheilkd 220:384-390
17. Joussen AM, Fauser S, Krohne TU, Lemmen KD, Lang GE, Kirchhof B (2003) Diabetische Retinopathie: Pathophysiologie und Therapie einer hypoxieinduzierten Entzündung. Ophthalmologe 100:363-370
18. Kishimoto A, Takai Y, Mori T et al. (1980) Activation of calcium and phospholipid-dependent protein kinase by diacylglycerol, its possible relation to phosphatidylinositol turnover. J Biol Chem 255:2273-2276
19. Kreuzer J, Denger S, Schmidts A et al. (1996) Fibrinogen promotes monocyte adhesion via a protein kinase C dependent mechanism. J Mol Med 74:161-165
20. Lang GE, Kampmeier J (2002) Die Bedeutung der Proteinkinase C in der Pathophysiologie der diabetischen Retinopathie. Klin Monatsbl Augenheilkd 219:769-776
21. Lang GE (2004) Therapie der diabetischen Retinopathie mit Somatostatinanaloga. Ophthalmologe 101:290-293
22. Li PF, Maasch C, Haller H et al. (1999) Requirement for protein kinase C in reactive oxygen species-induced apoptosis of vascular smooth muscle cells. Circulation 100:967-973
23. Liao DF, Monia B, Dean N et al. (1997) Protein kinase C-ζ mediates angiotensin II activation of ERK1/2 in vascular smooth muscle cells. J Biol Chem 272:6146-6150
24. Malhotra A, Reich D, Nakouzi A et al. (1997) Experimental diabetes is associated with functional acitivation of protein kinase C epsilon and phosphorylation of troponin-I in the heart, which are prevented by angiotensin II receptor blockade. Circ Res 81:1027-1033
25. Massin P, Audren F, Haouchine B et al. (2004) Intravitreal Triamcinolone Acetonice for diabetic diffuse macular edema. Ophthalmology 111:218-225
26. Nishizuka Y (1988) The molecular etherogeneity of protein kinase C and its implication for cellular regulation. Nature 334:661-665
27. Poulsen JE (1966) Diabetes and anterior pituitary insufficiency: final course and postpartum study of a diabetic patient with Sheehan's syndrome. Diabetes 15:73-77
28. Spranger J, Mohlig M, Osterhoff M, Bühnen J, Blum WF, Pfeiffer AFH (2001) Retinal photocoagulation does not influence intraocular levels of IGF-1, IGF-and IGF-BP3 in proliferative diabetic retinopathy - evidence for combined treatment of PDR with somatostatinanalogues and retinal photocoagulation. Horm Met Res 33:312-316
29. Spraul CW, Baldysiak-Figiel A, Lang GK, Lang GE (2002) Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro. Graefes Arch Clin Exp Ophthalmol 240:227-231
30. Xia P, Inoguchi T, Kern TS et al. (1994) Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 43:1122-1129